The burden of illness of irritable bowel syndrome: current challenges and hope for the future.

  title={The burden of illness of irritable bowel syndrome: current challenges and hope for the future.},
  author={Darrell T. Hulisz},
  journal={Journal of managed care pharmacy : JMCP},
  volume={10 4},
  • D. Hulisz
  • Published 1 July 2004
  • Medicine
  • Journal of managed care pharmacy : JMCP
OBJECTIVES To review unmet medical needs associated with irritable bowel syndrome (IBS), to discuss factors that contribute to these unmet needs, and to provide an overview of advancements in IBS diagnosis and treatment options that may influence treatment strategies. SUMMARY IBS is characterized by a multiple symptom complex of abdominal pain or discomfort and altered bowel habits (i.e., constipation, diarrhea, or both in alternation) and is associated with a large unmet medical need. IBS… 

Tables from this paper

Optimal management of constipation associated with irritable bowel syndrome

A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder.

Updates on treatment of irritable bowel syndrome.

A physiologically-based overview of recently developed and frequently employed pharmaceutical agents used to treat IBS is provided, and some non-pharmaceutical options that may be beneficial in this disorder are discussed.

Diet Therapy in Irritable Bowel Syndrome; A review

Foods containing gluten, lactose, fructose, galactane, sorbitol, fructane and allergen foods should be limited or omitted and patients should be advised to use fibers, prebiotics and probiotics more often.

Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

A narrative review covers the spectrum of available drugs and their mechanisms of action, as well as the efficacy and safety profiles of each as determined in relevant clinical trials that have investigated treatment options for IBS-C and chronic constipation.

Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases

The burden of illness of IBS in the Netherlands is substantial and IBS patients treated with mebeverine experienced low quality of life and suffered from severe pain.


Food containing gluten, lactose, fructose, galactane, sorbitol, fructane and allergen foods should be limited or omitted and patients should be advised to use fibers, prebiotics and probiotics more often.

A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.

A large variation in attributable direct and indirect costs and drivers of these costs was observed and future research should refine burden of illness estimates to subtypes so that estimates associated with IBS-C and CC are differentiated.

Overview of Irritable Bowel Syndrome (IBS)

This article is the overview of irritable bowel syndrome, a chronic functional disorder of the gastrointestinal tract with symptoms of abdominal pain and altered bowel habits that include diarrhea, constipation, or both.

Multidimensionality of symptom complexes in irritable bowel syndrome and other functional gastrointestinal disorders.

  • D. Alpers
  • Medicine
    Journal of psychosomatic research
  • 2008

Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.

IBS-D was associated with a substantial burden in direct costs in this population of commercially insured patients and incurred significantly more annual all-cause health care costs, even after controlling for demographics and comorbidities.



Treatment goals in irritable bowel syndrome.

  • J. Kellow
  • Medicine
    International journal of clinical practice
  • 2001
Recent clinical trials suggest that 5-HT4 receptor partial agonists, in particular, may have the ability to offer multiple symptom relief, without the risk of significant adverse reactions.

Irritable bowel syndrome: evaluation and treatment.

Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United Kingdom

IBS has a significant impact on quality of life and resource use in both the US and UK, and appears to be greater in the UK than in the US, while the general health status of persons with IBS in either country was much poorer.

AGA technical review on irritable bowel syndrome.

Psychosocial factors, although not part of IBS per se, have an important role in modulating the illness experience and its clinical outcome.

A systematic review of alternative therapies in the irritable bowel syndrome.

A variety of treatments that exist beyond the scope of commonly used therapies for irritable bowel syndrome are explored, and Guarded optimism exists for traditional Chinese medicine and psychological therapies, but further well-designed trials are needed.

Irritable Bowel Syndrome, Health Care Use, and Costs: A U.S. Managed Care Perspective

It is found that IBS is associated with a broad pattern of increased health care use and costs and the severity of abdominal pain/discomfort is a significant predictor of health careUse and costs for patients with IBS compared with non-IBS subjects.

Emerging treatments for irritable bowel syndrome

Conventional treatments for irritable bowel syndrome are outlined and the data on emerging and experimental therapies for IBS are reviewed, which require more studies before they can be utilised as clinical treatments.

Comorbidity of irritable bowel syndrome in psychiatric patients: a review.

The article reviews the comorbidity of IBS in psychiatric patients and discusses implications for treatment.

The impact of irritable bowel syndrome on health-related quality of life.

Comparisons with previously reported HRQOL data for the general U.S. population and for patients with gastroesophageal reflux disease, diabetes mellitus, depression, and dialysis-dependent end-stage renal disease offer further insight into the impact of IBS on patient functional status and well-being.